Cargando…

Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine

BACKGROUND: Currently licensed human vaccines are subtype-specific and do not protect against pandemic H5N1 viruses. Previously, our group has reported on the construction of an influenza virus-like particle (VLP) as a new generation candidate vaccine. A mixture of influenza H5N1 VLPs representing c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crevar, Corey J, Ross, Ted M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583969/ https://www.ncbi.nlm.nih.gov/pubmed/18957098 http://dx.doi.org/10.1186/1743-422X-5-131

Ejemplares similares

A Trivalent Virus-Like Particle Vaccine Elicits Protective Immune Responses against Seasonal Influenza Strains in Mice and Ferrets
por: Ross, Ted M., et al.
Publicado: (2009)

Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle
por: Bright, Rick A., et al.
Publicado: (2008)

Properly Folded Bacterially Expressed H1N1 Hemagglutinin Globular Head and Ectodomain Vaccines Protect Ferrets against H1N1 Pandemic Influenza Virus
por: Khurana, Surender, et al.
Publicado: (2010)

Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses
por: Skarlupka, Amanda L., et al.
Publicado: (2019)

The transmembrane replacement H7N9-VLP vaccine displays high levels of protection in mice
por: Qin, Jianru, et al.
Publicado: (2022)

A VLP Vaccine Induces Broad-Spectrum Cross-Protective Antibody Immunity against H5N1 and H1N1 Subtypes of Influenza A Virus
por: Wu, Chia-Ying, et al.
Publicado: (2012)

Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses
por: Allen, James D., et al.
Publicado: (2018)

Correction: Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses
por: Allen, James D., et al.
Publicado: (2018)

A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities
por: Hodgins, Breanna, et al.
Publicado: (2019)

Next Generation of Computationally Optimized Broadly Reactive HA Vaccines Elicited Cross-Reactive Immune Responses and Provided Protection against H1N1 Virus Infection
por: Huang, Ying, et al.
Publicado: (2021)

A bivalent live-attenuated vaccine candidate elicits protective immunity against human adenovirus types 4 and 7
por: Guo, Jingao, et al.
Publicado: (2021)

Complex Patterns of Human Antisera Reactivity to Novel 2009 H1N1 and Historical H1N1 Influenza Strains
por: Carter, Donald M., et al.
Publicado: (2012)

A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
por: Goksøyr, Louise, et al.
Publicado: (2022)

Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza
por: Ross, Ted, et al.
Publicado: (2010)

Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses
por: Ouyang, Maggie Jing, et al.
Publicado: (2023)

Passive Immunity and Antibody Response Induced by Toxoplasma gondii VLP Immunization
por: Kang, Hae-Ji, et al.
Publicado: (2021)

Bivalent Norovirus VLP Vaccine Candidate in Older Adults: Impact of MPL and a Second Dose in a Randomized, Controlled, Double-Blind Clinical Trial
por: Sherwood, Jim, et al.
Publicado: (2017)

Human immune responses elicited by an intranasal inactivated H5 influenza vaccine
por: Ainai, Akira, et al.
Publicado: (2020)

Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice
por: Zhao, Zhimin, et al.
Publicado: (2021)

A DNA inducing VLP vaccine designed for HIV and tested in mice
por: Calazans, Alexandre, et al.
Publicado: (2017)

T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection
por: Cooper, Christopher L, et al.
Publicado: (2017)

RNA Phage VLP-Based Vaccine Platforms
por: Peabody, David S., et al.
Publicado: (2021)

A VLP-Based Vaccine Displaying HBHA and MTP Antigens of Mycobacterium tuberculosis Induces Protective Immune Responses in M. tuberculosis H37Ra Infected Mice
por: Wang, Juan, et al.
Publicado: (2023)

Historical H1N1 Influenza Virus Imprinting Increases Vaccine Protection by Influencing the Activity and Sustained Production of Antibodies Elicited at Vaccination in Ferrets
por: Francis, Magen E., et al.
Publicado: (2019)

A Candidate H1N1 Pandemic Influenza Vaccine Elicits Protective Immunity in Mice
por: Steitz, Julia, et al.
Publicado: (2010)

Virus-like particle (VLP)-based vaccines for pandemic influenza: Performance of a VLP vaccine during the 2009 influenza pandemic
por: López-Macías, Constantino
Publicado: (2012)

VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation
por: Daly, Seth M., et al.
Publicado: (2017)

Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge
por: Eugene, Hermancia S, et al.
Publicado: (2013)

The mucosal and systemic immune responses elicited by a chitosan‐adjuvanted intranasal influenza H5N1 vaccine
por: Svindland, Signe C., et al.
Publicado: (2011)

Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice
por: Wong, Gary, et al.
Publicado: (2015)

DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2018)

Influence of the H1N1 influenza pandemic on the humoral immune response to seasonal flu vaccines
por: Jang, Hyesun, et al.
Publicado: (2021)

2276. Immunogenicity of Takeda’s Bivalent Virus-Like Particle (VLP) Norovirus Vaccine (NoV) Candidate in Children From 6 Months up to 4 Years of Age
por: Masuda, Taisei, et al.
Publicado: (2018)

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
por: Waerlop, Gwenn, et al.
Publicado: (2023)

Protection of Cattle Elicited Using a Bivalent Lumpy Skin Disease Virus-Vectored Recombinant Rift Valley Fever Vaccine
por: Wallace, David B., et al.
Publicado: (2020)

Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters
por: Berry, Catherine, et al.
Publicado: (2023)

Zika virus-like particle (VLP) based vaccine
por: Boigard, Hélène, et al.
Publicado: (2017)

Large-scale production and purification of VLP-based vaccines
por: Vicente, Tiago, et al.
Publicado: (2011)

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023)

Nanoparticle-Based Bivalent Swine Influenza Virus Vaccine Induces Enhanced Immunity and Effective Protection against Drifted H1N1 and H3N2 Viruses in Mice
por: Tang, Pan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0orh77nt8fb6scqenujgv4dusv